Global Tecentriq (Atezolizumab; Roche/Chugai) Market Outlook to 2026 - ResearchAndMarkets.com

DUBLIN--()--The "Tecentriq" drug pipelines has been added to ResearchAndMarkets.com's offering.

Tecentriq (atezolizumab; Roche/Chugai) is a fully humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1).

PD-L1 is expressed on the surface of antigen-presenting cells and some tumor cells. PD-L1 binds to programmed death-1 (PD-1) co-inhibitory receptors which are expressed on the surface of T cells after T-cell activation. The receptor ligand interaction produces inhibitory signals which regulate T-cell activation and promote immune tolerance, which favors tumor progression.

By blocking the PD-L1/PD-1 interaction, Tecentriq enables T-cell activation and allows the immune system to mount a more effective anti-tumor response.

Key Topics Covered

  1. Drug Overview
  2. Product Profiles
  3. Tecentriq : Non-small cell lung cancer (NSCLC)
  4. Tecentriq : Melanoma
  5. Tecentriq : Prostate cancer
  6. Tecentriq : Colorectal cancer (CRC)
  7. Tecentriq : Ovarian cancer
  8. Tecentriq : Bladder cancer
  9. Tecentriq : Renal cell cancer (RCC)
  10. atezolizumab : Breast cancer: triple-negative

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/floh1e

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Lung Cancer Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Lung Cancer Drugs